270 related articles for article (PubMed ID: 33008815)
1. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.
Abdallah N; Baughn LB; Rajkumar SV; Kapoor P; Gertz MA; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Ketterling R; Bergsagel L; Greipp P; Kumar SK
Clin Cancer Res; 2020 Dec; 26(24):6581-6588. PubMed ID: 33008815
[TBL] [Abstract][Full Text] [Related]
2. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J
Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491
[TBL] [Abstract][Full Text] [Related]
3. Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
Glitza IC; Lu G; Shah R; Bashir Q; Shah N; Champlin RE; Shah J; Orlowski RZ; Qazilbash MH
Leuk Lymphoma; 2015 Mar; 56(3):602-7. PubMed ID: 24844357
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response.
Abdallah N; Rajkumar SV; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Kumar SK
Blood Cancer J; 2020 Aug; 10(8):82. PubMed ID: 32782240
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
[TBL] [Abstract][Full Text] [Related]
7. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
8. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.
Laï JL; Zandecki M; Mary JY; Bernardi F; Izydorczyk V; Flactif M; Morel P; Jouet JP; Bauters F; Facon T
Blood; 1995 May; 85(9):2490-7. PubMed ID: 7537117
[TBL] [Abstract][Full Text] [Related]
9. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Taddesse-Heath L; Meloni-Ehrig A; Scheerle J; Kelly JC; Jaffe ES
Mod Pathol; 2010 Jul; 23(7):991-9. PubMed ID: 20348882
[TBL] [Abstract][Full Text] [Related]
10. Nationwide study of pediatric B-cell precursor acute lymphoblastic leukemia with chromosome 8q24/MYC rearrangement in Japan.
Sakaguchi K; Imamura T; Ishimaru S; Imai C; Shimonodan H; Fujita N; Okada K; Taketani T; Kanai R; Tauchi H; Kato M; Kojima Y; Watanabe A; Deguchi T; Hashii Y; Kiyokawa N; Taki T; Saito AM; Horibe K; Manabe A; Sato A; Koh K
Pediatr Blood Cancer; 2020 Jul; 67(7):e28341. PubMed ID: 32323914
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of c-myc is associated with adverse clinical features and worse overall survival in multiple myeloma.
Szabo AG; Gang AO; Pedersen MØ; Poulsen TS; Klausen TW; Nørgaard P
Leuk Lymphoma; 2016 Nov; 57(11):2526-34. PubMed ID: 27243588
[TBL] [Abstract][Full Text] [Related]
12. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
Abdallah N; Greipp P; Kapoor P; Gertz MA; Dispenzieri A; Baughn LB; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Go RS; Hwa YL; Fonder A; Hobbs M; Lin Y; Leung N; Kourelis T; Warsame R; Siddiqui M; Lust J; Kyle RA; Bergsagel L; Ketterling R; Rajkumar SV; Kumar SK
Blood Adv; 2020 Aug; 4(15):3509-3519. PubMed ID: 32750129
[TBL] [Abstract][Full Text] [Related]
14. High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Schrader AMR; Jansen PM; Vermeer MH; Kleiverda JK; Vermaat JSP; Willemze R
Am J Surg Pathol; 2018 Nov; 42(11):1488-1494. PubMed ID: 30113335
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
Wang Y; Li Q; Xing S; Zhang H; Li D
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
[TBL] [Abstract][Full Text] [Related]
16. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
18. Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.
Sekiguchi N; Ootsubo K; Wagatsuma M; Midorikawa K; Nagata A; Noto S; Yamada K; Takezako N
Int J Hematol; 2014 Mar; 99(3):288-95. PubMed ID: 24496825
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA T-cell factor 7 in multiple myeloma: A potential biomarker for deteriorated clinical features and poor prognosis.
Zhang C; Chu M; Fan Y; Wu L; Li Z; Ma X; Zhuang W
J Clin Lab Anal; 2020 Sep; 34(9):e23400. PubMed ID: 32578294
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
